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aCetylsaliCyliC aCid in Patients with CardioVasCular disease for 
stroke PreVention in ukraine
Mishchenko O., Iakovlieva L., Adonkina V., Kyrychenko O., Gerasymovà O.
National University of Pharmacy, Kharkiv, Ukraine
Objectives: The results of many clinical trials demonstrate the benefit of long-
term antiplatelet therapy in reducing the risk of cardio- and cerebrovascular com-
plications. Both acetylsalicylic acid (ASA) and clopidogrel are effective, but have 
potentially serious side effects, and clopidogrel is more expensive than ASA. The 
purpose of the study is to evaluate the pharmacoeconomic acceptance of clopi-
dogrel versus ASA in patients with atherosclerotic vascular disease manifested 
as either recent ischaemic stroke, recent myocardial infarction, or symptomatic 
peripheral arterial disease to prevent non-fatal stroke and death rate according to 
the clinical trial CAPRIE from Ukrainian perspective. MethOds: Outcomes of the 
clinical study CAPRIE, modeling “decision tree” and analysis “cost-effectiveness” 
were used. Results: The results of the clinical trial CAPRIE study showed, that 
clopidogrel is more effective versus ASA for reducing the risk of nonfatal stroke: 
absolute risk reduction is -2.7%. Model “decision tree” was built using the probabili-
ties of events (nonfatal stroke and death) from the study CAPRIE. Direct costs were 
calculated taking into account the costs of antiplatelet therapy, of nonfatal stroke 
treatment (drugs, diagnosis, patient’s stay in hospital) and the cost of rehabilita-
tion after stroke. Indirect costs are not taken into account because the patients 
were of retirement age (62.5 years old). As a result of calculations it was found, 
that antiplatelet therapy with clopidogrel is more expensive and more effective (2 
additional lives saved per 1000 patients over 1.91 years) compared with ASA. Due 
to the threshold of society “willingness to pay” per 1 life saved, or 1 QALY, use of 
clopidogrel as antiplatelet agent in patients with cardiovascular disease is economi-
cally profitable for Ukraine. cOnclusiOns: The use of clopidogrel as an antiplatelet 
agent in patients with cardiovascular disease to prevent nonfatal stroke compared 
to the ASA is economically profitable for Ukraine.
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Objectives: Stroke and its associated disability costs the European Union an esti-
mated € 62 billion per year. Warfarin is the mainstay for stroke prevention in atrial 
fibrillation (AF), but many patients have absolute contraindications to this drug. The 
Watchman device for left atrial appendage closure (LAAC) received CE mark for stroke 
prevention in AF patients with contraindications to warfarin. This analysis sought to 
estimate the cost effectiveness of treating warfarin-ineligible AF patients with LAAC 
as compared to standard aspirin therapy. MethOds: A Markov model was developed 
comparing clinical outcomes and total costs between patients treated with LAAC or 
aspirin over 5 and 10 years based largely on clinical outcomes from the Aspirin and 
Plavix Registry (ASAP) and ACTIVE trials. Clinical events included ischemic stroke, 
TIA, systemic embolism, bleeding, and acute myocardial infarction as well as proce-
dure-related events. Germany was chosen as the country of analysis because of its 
unique DRG for the LAAC procedure. Acute costs were taken from German DRGs and 
long-term disability costs were taken from the Berlin Acute Stroke Study. Sensitivity 
analysis was performed on clinical and cost inputs; the model was most sensitive 
to changes in the rate of ischemic stroke. Results: LAAC demonstrated a benefit 
in terms of ischemic strokes and mortality avoided. The cost per ischemic stroke 
avoided was € 91,020 and € 24,722 at 5 and 10 years, respectively. The cost per life year 
gained for LAAC versus aspirin was € 22,694 at 5 years and decreased to € 5,859 at 
10 years. cOnclusiOns: LAAC is a cost-effective alternative to aspirin therapy in 
patients with contraindications to warfarin. Cost offsets achieved with LAAC become 
considerably more pronounced over time. This analysis highlights the importance of 
considering the lifetime costs of stroke prevention in AF, especially as the probability 
of both stroke and bleeding increases with patient age.
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Objectives: To perform a cost-effectiveness analysis of rivaroxaban (once-daily) in 
the prevention of stroke and systemic embolism of patients with non-valvular atrial 
fibrillation (NVAF) and in patients sub-groups from the perspective of the Italian 
health care system (SSN). MethOds: A Markov model was developed with a life-
time timeframe where a hypothetic NVAF patients’ cohort is treated with Vitamin-K 
antagonists (VKAs), antiplatelet drugs (ASA) or no therapy. Patients remain stable 
or progress towards other health states (ischemic or hemorrhagic stroke, myocar-
dial infarction and bleedings) until death. The base case compares rivaroxaban 
with VKAs. In subgroup analyses, rivaroxaban is compared with patients at highest 
unmet medical need: 1. VKA patients with poor INR control, 2. patients under ASA 
or 3. not treated. Clinical data were derived from ROCKET-AF trial or a network 
meta-analysis. Utility data were retrieved from published literature. Health care 
resources consumption was valued using average regional tariffs in Italy. Since 
rivaroxaban price is not officially published, the price of the first novel oral antico-
agulant approved in this indication in Italy was considered. Model outcomes are 
expressed in terms of incremental cost per quality adjusted life year (QALY) gained 
(ICER). Univariate and probabilistic sensitivity analyses were performed Results: 
In the base case, rivaroxaban showed to be cost-effective compared to VKA with an 
VKA-unsuitable, respectively) formed the basis of the analysis. Clinical events 
(ischemic strokes, hemorrhagic strokes, intracranial hemorrhages, other major 
bleeds, clinically relevant non-major bleeds, myocardial infarctions and car-
diovascular hospitalizations) were modeled over a lifetime horizon based on 
the clinical efficacy of each comparator, as reported by two phase-III clini-
cal trials (ARISTOTLE and AVERROES). Resource use with regards to patient 
monitoring was elicited via an experts’ panel (cardiologists & internists). 
Cost calculations reflect the local clinical setting, and followed a third-party 
payer perspective (Euros, year 2013, discounted at 3%). Results: Apixaban 
was projected to reduce the occurrence of clinical events and increase quality 
adjusted life expectancy compared to warfarin and aspirin (an incremental 
increase of 0.225 and 0.274 QALYs per patient, respectively). Taking into account 
costs of medications, treatment and management of events, the incremental 
cost-effectiveness ratio for apixaban versus warfarin and aspirin was esti-
mated at 12,154.6 € /QALY and 5,980.6 € /QALY gained, respectively. Extensive 
sensitivity analyses indicated that results were robust over a wide range of 
inputs. cOnclusiOns: Based on the results of this analysis, apixaban can 
be a cost-effective alternative to warfarin and aspirin for the management of 
VKA-suitable and VKA-unsuitable patients with NVAF, respectively, in Greece.
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Objectives: Intravascular ultra-sound (IVUS) allows physicians to generate a supe-
rior image of coronary arteries during percutaneous coronary interventions (PCI), 
providing a tomographic, 360-degree view of the arterial wall from the inside, which 
allows a more accurate and complete assessment than is possible with angiography. 
The purpose of this study was to understand the cost-effectiveness of IVUS com-
pared with traditional angiography techniques in drug-eluting stent (DES) implanta-
tion, from the perspective of the Italian health system. MethOds: A Markov model 
was developed to extrapolate the comparative costs and outcomes of a theoretical 
population of 1000 patients undergoing DES implantation with traditional angiogra-
phy alone, or in conjunction with IVUS. The model assesses cardiac events, including 
revascularisations and myocardial infarctions from a health system perspective. 
Outcomes with and without IVUS were based on a meta-analysis by Zhang et al 
(2013). Because of limited clinical evidence to inform the long-term outcomes of 
IVUS compared with angiography, the model either assumes the benefit of IVUS 
is conferred only in the first year of treatment, or that the benefit is maintained 
permanently. Results: Using IVUS during PCI cost an average of € 542 per patient, 
and yields an additional 0.022 quality adjusted life years (QALYs) per patient. In a 
population of 1,000 patients, IVUS led to a reduction of 6.7 revascularisations and 
5.9 less myocardial infarctions (MI) over the lifetime of a patient. When the revas-
cularisation and MI benefit of IVUS is assumed to extend for the patient’s lifetime, 
angiography with IVUS costs € 38 per patient and yields an additional 0.09 QALYs 
over a patient’s lifetime; avoiding 13.4 MIs and 12.3 revascularisations per 1,000 
patients. cOnclusiOns: IVUS appears to be a cost-effective addition to traditional 
angiography in DES placement in Italy, with the increased upfront cost of IVUS offset 
by reduced cardiac events in IVUS-treated patients over time.
PCV77
Cost-effeCtiVeness of aPixaban Versus other new oral 
antiCoagulants for the PreVention of stroke: an analysis of 
Patients with atrial fibrillation in greeCe
Athanasakis K.1, Arzoumanidou D.1, Karampli E.1, Armelidou E.2, Giovas P.2, Petrikkou E.3, 
Kyriopoulos J.1
1National School of Public Health, Athens, Greece, 2Pfizer Hellas, Athens, Greece, 3BMS Hellas, 
Athens, Greece
Objectives: Apixaban, dabigatran (150 mg BID and 110 mg BID) and rivaroxaban 
are three novel oral anticoagulants (NOACs) currently approved for stroke preven-
tion and systemic embolism in non-valvular atrial fibrillation (NVAF) patients. 
The objective of this analysis was to assess the cost-effectiveness (CE) of apixa-
ban against other NOACs for the prevention of stroke in patients with NVAF in 
Greece. MethOds: A Markov model that evaluated clinical events, quality adjusted 
life expectancy and costs for patients treated with apixaban or other NOACs formed 
the basis of the analysis. Clinical events (ischemic strokes, hemorrhagic strokes, 
intracranial hemorrhages, other major bleeds, clinically relevant non-major bleeds, 
myocardial infarctions and cardiovascular hospitalizations) were modeled for a 
lifetime horizon. Due to lack of head-to-head comparisons, efficacy and safety data 
was derived from an indirect treatment comparison (ITC). The key pivotal trials, 
ARISTOTLE, ROCKET-AF and RE-LY, all included warfarin as a comparator therefore 
allowing for an ITC. Resource use with regards to patient monitoring was elic-
ited via a panel of experts (cardiologists & internists). Cost calculations reflect the 
local clinical setting and followed a third-party payer perspective (Euros, year 2013, 
discounted at 3%). Results: Apixaban was projected to reduce the occurrence of 
clinical events and increase quality-adjusted life expectancy and costs of treatment 
compared to other NOACs. Taking into account costs of medications, treatment 
and management of events, the incremental cost-effectiveness ratios for apixaban 
5 mg BID versus dabigatran 150 mg BID, dabigatran 110 mg BID and rivaroxaban 
20 mg QD were estimated at 15,403€ /QALY, 4,955€ /QALY and 10,130 € /QALY gained, 
respectively. Extensive sensitivity analyses indicated that results were robust over a 
wide range of inputs. cOnclusiOns: Based on the results of this analysis, apixaban 
can be a cost-effective alternative to other NOACs, for the prevention of strokes in 
patients with NVAF in Greece.
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using the UKPDS risk engine. Statin adherence was measured as pill days cov-
ered (PDC) in the IADB.nl pharmacy research database. Cost-effectiveness was 
measured in costs per quality-adjusted life-year (QALY) form the health care-
payers’ perspective. Results: For an average patient aged 60 at diagnosis, statin 
treatment was highly cost-effective at around € 2,300 per QALY. Favourable cost-
effectiveness was robust in sensitivity analysis. Differences in age and 10-year 
cardiovascular risk showed large differences in cost-effectiveness from more 
than € 100,000 per QALY to almost being cost saving. For the average patient aged 
40 at diabetes diagnosis, statin treatment for primary prevention was not cost-effec-
tive. cOnclusiOns: Despite the non-adherence levels observed in actual practice, 
statin treatment is cost-effective for primary prevention in patients newly diagnosed 
with type 2 diabetes. Due to large differences in cost-effectiveness according to differ-
ent risk and age groups, the efficiency of the treatment could be increased by targeting 
patients with relatively higher cardiovascular risk and higher ages.
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Objectives: Patients with a recent transient ischemic attack (TIA) or minor ischemic 
stroke who receive medicines have a 10-year risk of about 16% for any recurrent 
stroke. Non-invasive molecular imaging technologies are currently being developed 
to improve individual stroke risk prediction. We estimated the potential lifetime cost-
effectiveness of a novel imaging test for stroke prediction in an early stage of develop-
ment. MethOds: Decision modelling was used to estimate the potential value of an 
add-on test that could identify which patients with a recent TIA or minor ischemic 
stroke should undergo surgery instead of receive medicines. The comparator was 
patient management according to Dutch guidelines. Test sensitivity and specificity 
were varied from 0-100% and its cost was set at € 350. Different age- and gender-spe-
cific subgroups were examined to see how much cost-effectiveness varied. Results: 
A perfect add-on test (100% sensitivity and specificity) for 60-year-old men appears to 
be cost-effective versus Dutch guidelines, with an estimated 0.61 QALY gain, € 3,986 
cost increase, and an incremental cost-effectiveness ratio (ICER) of € 6,534/QALY 
gained. A test with sensitivity= 60% and specificity= 100% increases both health (0.14 
QALYs) and costs (€ 2,888), resulting in an ICER of € 20,338/QALY gained. Similarly, a 
test with sensitivity= 100% and specificity= 60% increases both health (0.29 QALYs) 
and costs (€ 5,784), resulting in an ICER of € 19,946/QALY gained. cOnclusiOns: An 
imaging test that improves risk prediction and therefore treatment decisions for 
patients with a recent TIA or minor ischemic stroke has the potential to optimize cost-
effectiveness by reducing the risk of recurrent stroke. However, reduced sensitivity 
or specificity of the test reduces its cost-effectiveness versus the Dutch guidelines. 
Developers must consider if the minimum level of accuracy required to be cost-effec-
tive is close to the maximum capability of the test. Model-based analyses are valu-
able in facilitating decisions about investments in the further development of a test.
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Objectives: At the population level, disease management programs (DMPs) for heart 
failure (HF) have proven to be effective in increasing quality-adjusted survival and 
reducing the rate of hospital readmission. However, a systematic assessment as to 
whether these outcomes could still be improved upon by tailoring the content and 
structure of such DMPs to the risk profile of the individual patient has not yet been 
conducted. Using data from a previously conducted randomized controlled trial, the 
purpose of this study was to explore the clinical and health economic consequences 
of assigning different DMPs to different risk categories of HF patient. MethOds: The 
analysis was conducted alongside the COACH study, in which 1023 patients were ran-
domly assigned to one of three DMPs: care-as-usual (routine follow-up by a cardiolo-
gist), basic additional support by a nurse specialized in HF management (HF-nurse), 
and intensive additional support by an HF-nurse. The Subpopulation Treatment Effect 
Pattern Plot (STEPP) methodology was applied to graphically establish suitable cut-
offs for stratifying patients into different risk categories based on their predicted 
18-month mortality risk. Separate cost-effectiveness analyses were subsequently 
performed within each of these strata to determine per risk category the DMP that 
would be optimal in terms of survival time and costs. Results: Based on the STEPP 
analysis, a cut-off of 0.17 was selected to classify 346 (33.8%) patients as low risk and 
677 (66.2%) patients as high risk. At a threshold value of € 10,000 per life-year, this 
resulted in an 82.9% probability that intensive support would be optimal for low-risk 
patients and an 83.6% probability that basic support would be optimal for high-risk 
patients. cOnclusiOns: Assigning different DMPs to different risk groups of patient 
improved outcomes and reduced costs. Tailoring the content and structure of such 
programs to the risk profile of the individual patient seems therefore desired.
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Objectives: Dabigatran was recommended by the Pharmaceutical Benefits 
Advisory Committee (PBAC) in March 2011 for the treatment of non-valvular atrial 
fibrillation (NVAF) but was not listed on the Pharmaceutical Benefits Scheme (PBS) 
for over two years. This analysis examines the cost-effectiveness of dabigatran 
and the opportunity cost of delayed reimbursement from a societal perspec-
tive. MethOds: This analysis estimated the costs for dabigatran compared with 
warfarin and a mixed comparator (warfarin/aspirin/untreated) reflective of current 
ICER of € 11,000/QALY which is below the threshold deemed acceptable from Italian 
payers (25.000€ -40.000€ ). In the subgroups analyses, rivaroxaban demonstrated to 
be a dominant strategy (more effective and less costly). Sensitivity analyses showed 
the robustness of the results. cOnclusiOns: Rivaroxaban is a cost-effective alter-
native to VKA and is cost-saving for the SSN in the treatment of NVAF patients at 
highest unmet medical need.
PCV81
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Objectives: To estimate the cost-effectiveness of dabigatran etexilate (dabigatran) 
for the secondary prevention of deep vein thrombosis (DVT) and pulmonary embo-
lism (PE) from the perspective of the UK National Health Service. MethOds: A 
Markov model was developed to estimate costs and outcomes over the lifetime of 
a cohort of patients receiving either dabigatran (150mg given orally, twice daily) 
or placebo for 6 months after having completed 6 to 18 months of anticoagulation 
treatment for a DVT or PE. Modelled events included recurrent DVT and PE, major 
bleeding (including long-term disability from intracranial haemorrhage), clinically 
relevant non-major bleeding, myocardial infarction, unstable angina, pulmonary 
hypertension, severe postthrombotic syndrome, and death. Efficacy and safety 
parameters were based on the RE-SONATE study; the period of follow-up was 6 
months with an extension to 18 months. Probabilities of recurrent DVT and PE after 
trial follow-up were based on a prospective cohort study of 1,626 patients followed-
up for a median of 50 months and were assumed to be equivalent in both treatment 
groups. Utility estimates were based on EQ-5D data collected in dabigatran trials and 
published literature. The mean duration of therapy was based on the RE-SONATE 
study; other costs were based on NHS Reference Costs and published literature. 
Costs and outcomes were discounted at 3.5% per annum. Univariate and probabilis-
tic sensitivity analyses were performed. Results: In the base-case analysis, mean 
total costs for dabigatran and placebo patients were £7,147 and £7,520 respectively; 
mean QALYs were 13.089 and 13.070 respectively. Dabigatran was dominant; the 
probability of cost-effectiveness at a willingness-to-pay threshold of £20,000 per 
QALY was 63%. In univariate sensitivity analysis, dabigatran was dominant in all 
analyses. cOnclusiOns: This analysis suggests that dabigatran is likely to be cost-
saving compared to placebo for the secondary prevention of DVT and PE in the UK.
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Objectives: Statins are the standard treatment for cardiovascular disease (CVD) 
prevention however, with limited effect on triglyceride (TG) and high-density lipo-
protein-cholesterol (HDL-C) in mixed hyperlipidemia. Fenofibric acid (FA) is approved 
for co-administration with statins to reduce TG and increase HDL-C in patients with 
mixed hyperlipidemia at goal for LDL-C with statins. This study assesses the cost-
effectiveness of FA combined with low (LDS) or medium (MDS) dose statins versus 
low, medium or high (HDS) dose statins alone in the prevention of CVD in Taiwanese 
patients with type 2 diabetes and mixed hyperlipidemia. MethOds: A 5-health-
state Markov model for diabetic patients with mixed hyperlipidemia already 
treated with statin (TG:250mg/dl; HDL-C:35mg/dl; LDL-C:115mg/dl; TC:200mg/dl) 
was developed, using a lifetime horizon with annual cycles. PROCAM (first event) 
and Framingham (subsequent event) risk equations were used. Effects on TG, HDL-C 
and TC for each comparator were derived from pooled simvastatin, atrovastatin 
and rosuvastatin trials. Drug and event costs were based on official national data-
bases. Annual discounting (5%) was applied to outcomes and costs. Incremental cost 
(€ ) per Quality of Life Gained (QALYG) was calculated from the Taiwanese Bureau 
of National Health Insurance perspective. Results: Compared to LDS and MDS, 
treatment with FA+LDS resulted in higher costs (€ 2,225; € 1,676) but more QALYG 
(0.311; 0.064), resulting in an incremental cost-effectiveness ratio of € 7,161/QALYG 
and € 26,375/QALYG respectively. Compared to HDS, FA+LDS costs were lower with 
slightly less QALYG (ICER: € 183,490/QALYG). Compared to FA+MDS, FA+LDS was 
dominant with lower costs (-€ 900) and higher QALYG (0.004). Sensitivity analyses 
showed robustness of the results. The probability for FA+LDS being cost-effective 
(< GDP threshold € 45,400) is 100% for both, LDS and MDS. cOnclusiOns: In this 
specific mixed hyperlipidemia population, FA+LDS is likely to be a cost-effective 
alternative to LDS or MDS alone, potentially allowing for lower statin doses in pre-
venting CVD.
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Objectives: Statins reduce the risk of cardiovascular events in patients 
with diabetes. The aim of this study is to determine whether statin treatment 
for primary prevention in newly diagnosed type 2 diabetes is cost-effective, 
taking non-adherence, baseline risk, and age into account. MethOds: A cost-
effectiveness analysis was performed using a Markov model with a time horizon 
of 10 years. The baseline 10-year cardiovascular risk was estimated in a Dutch 
population of primary prevention patients with newly diagnosed diabetes from 
the Groningen Initiative to Analyse Type 2 Diabetes Treatment database (GIANTT), 
